Cargando…

BRCA1 founder mutations and ovarian cancer in Belarus

Detalles Bibliográficos
Autores principales:	Savanevich, A, Ashuryk, A, Lubinski, J, Gronwald, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565623/ http://dx.doi.org/10.1186/1897-4287-13-S1-A3

Ejemplares similares

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Vitamins A, E and D and cancer risk in BRCA1 carriers
por: Kąklewski, K, et al.
Publicado: (2012)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
por: Ertmański, S, et al.
Publicado: (2012)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

BRCA1 mutation analysis in breast and ovarian cancer families from Greece
por: Konstantopoulou, I, et al.
Publicado: (2000)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

Prostate cancer screening based on genotyping for high risk founder alleles
por: Cybulski, Cezary, et al.
Publicado: (2012)

A Founder Mutation of the BRCA1-Gene in Western Sweden
por: Einbeigi, Zakaria, et al.
Publicado: (1999)

The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort
por: Sawyer, S, et al.
Publicado: (2012)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast cancer
por: Martínez-Ferrandis, JI, et al.
Publicado: (2000)

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations
por: Ghimenti, C, et al.
Publicado: (2000)

P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers
por: Sensi, E, et al.
Publicado: (2000)

Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes
por: Budryk, M, et al.
Publicado: (2012)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Alcohol: use and related problems - prevalence among foreigners and the natives in Belarus
por: Welcome, Menizibeya, et al.
Publicado: (2010)

Selenium (Se) and the risk of breast, ovarian and prostate cancers
por: Jaworska, Katarzyna, et al.
Publicado: (2012)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006)

BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
por: Ławniczak, Małgorzata, et al.
Publicado: (2016)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Testing the pyramidal hypothesis of alcohol use distribution among the Nigerians, Arabs and Slavs in Belarus
por: Osain, Menizibeya Welcome, et al.
Publicado: (2010)

From juniors to seniors: pattern of rise of alcohol problems among university students in Belarus
por: Osain, Menizibeya Welcome, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_42cs8p9hns9cie853thu9ap1h2